Last Updated : July 15, 2022
Trace amine-associated receptor 1 (TAAR1) agonists are an emerging drug class in the treatment of schizophrenia. Currently available antipsychotic therapies for schizophrenia act by blocking dopamine D2 receptors, which is associated with an increased risk of metabolic and motor side effects. TAAR1 agonists offer a novel mechanism of action as they act without D2 binding. This Horizon Scan Bulletin provides an early assessment of the evidence on TAAR1 agonists in development for schizophrenia and discusses considerations with regards to their uptake in Canada.